Belantamab (TNFRSF17/CD269) - Research Grade Biosimilar

• Background:

  Belantamab mafodotin (GSK2857916) is antibody-conjugated drug that connects humanized anti-BCMA antibodies with cytotoxic agents, and specifically targets BCMA to deliver cytotoxic agents into MM cells to kill cancer cells effect.

• Immunogen:

  Humanized / TNFRSF17/CD269 [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  IgG1-kappa

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  2857916, GSK2857916, J6M0, J6M0-mcMMAF